Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

142.70 -0.76 (-0.53%)
Streaming Delayed Price Updated: 10:00 AM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Animal Health Giant Zoetis Stock Crumbles: Possible Side Effect Of Its Pet Arthritis Pain Drugs Sickened Dogs, Cats
Zoetis' Solensia and Librela, pioneering arthritis treatments for pets. Despite recent concerns, Zoetis defends their safety record, emphasizing positive outcomes for millions of treated animals. 
Via Benzinga
A Closer Look at Zoetis's Options Market Dynamics
 
Via Benzinga
Zoetis Stock Crumbles After Report Suggests Arthritis Shots Sickened Dogs, Cats
The company says the side effects represent a fraction of the 18 million injections given in the U.S. and abroad. 
Via Investor's Business Daily
(ZTS) - Analyzing Zoetis's Short Interest
 
Via Benzinga
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry. 
Via The Motley Fool
Expert Outlook: Zoetis Through The Eyes Of 4 Analysts
 
Via Benzinga
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years
 
Via Benzinga
Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today
 
Via Benzinga
Looking Into Zoetis's Recent Short Interest
 
Via Benzinga
Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors
From Zoetis Inc.
Via Business Wire
Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks of March?
The S&P 500 rose last month, but these stocks didn't. 
Via The Motley Fool
Topics Stocks
Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results
From Zoetis Inc.
Via Business Wire
4 Analysts Have This To Say About Zoetis
 
Via Benzinga
(ZTS) - Analyzing Zoetis's Short Interest
 
Via Benzinga
Is ZOETIS INC (NYSE:ZTS) a Strong Candidate for Quality Investing?
Why Quality Investors Should Delve into ZOETIS INC (NYSE:ZTS) for Investment Opportunities. 
Via Chartmill
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
 
Via Benzinga
Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine
The European Commission launches probe into Zoetis over alleged market interference in dog pain medication launch. Focus on Zoetis' Librela monoclonal antibody for osteoarthritis pain relief in dogs... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Zoetis to Participate in the Barclays Global Healthcare Conference
From Zoetis Inc.
Via Business Wire
1 Magnificent S&P 500 Dividend Stock Down 23% to Buy Right Now
Buoyed by megatrends in animal healthcare, this stock makes for an excellent holding in almost any portfolio. 
Via The Motley Fool
Topics Stocks
Zoetis to Participate in the Bank of America Securities 2024 Animal Health Summit
From Zoetis Inc.
Via Business Wire
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
ZTS earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. 
Via Benzinga
Topics Economy Stocks
Animal Health-Focused Zoetis Stock Faces Near-Term Pressure, Analyst Cites Uncertainty In Q4 Results, Weak Margins
Zoetis' Q4 2023 performance with $2.21 billion revenue, 8% YoY growth, and strong sales in companion animal products. 
Via Benzinga
Zoetis Reports Fourth Quarter and Full Year 2023 Results
From Zoetis Inc.
Via Business Wire
Zoetis Declares Second Quarter 2024 Dividend
From Zoetis Inc.
Via Business Wire
Drug Maker AbbVie Stock Sees RS Rating Jump To 81
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Paws And Prosperity: Exploring U.S. Pet Services Growth And The Anticipated Surge In Annual Pet Spending From $980 To $1,292 By 2025
The number of U.S. homes with pets has been trending upward for decades, with more than 5 million more pets in the U.S. than before the pandemic. Beyond the pandemic-driven boom, the trends continue,... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.